Finn
ACAD Biotechnology · CNS drugs · Rare disease · Commercial biotech · Thesis updated November 8, 2026

Strong product sales offset a mixed pipeline trial result

01 Running thesis

Two growing drugs, one complicated pipeline

ACADIA sells two FDA-approved medicines and uses that cash to fund more CNS drug work. Q3 2026 showed exactly why the commercial setup is interesting. DAYBUE had $140 million of net sales and grew 39 percent year over year, driven by strong early demand for DAYBUE STIX. Management noted that over 50 percent of DAYBUE patients are now using the STIX formulation.

NUPLAZID remains the steadier part of the story. It had $202 million of Q3 2026 net sales, growing 12 percent year over year on an adjusted basis. The franchise is performing reliably as it tracks toward a management target of $1 billion in 2028 sales.

The European question for DAYBUE completely resolved after the European Commission officially approved the drug. This clears the final major regulatory hurdle and sets up the ongoing launch in Germany. Back in the US, a newly allowed patent extends protection for DAYBUE until March 2041.

The main swing factor is ACP-204, also called remlifanserin. Top-line Phase 2 results for Alzheimer's disease psychosis missed statistical significance on the primary endpoint. However, the 60mg dose showed enough activity for management to move forward with a modified Phase 3 trial. This shifts the pipeline narrative from an easy win to a high-stakes, complicated late-stage program.

Nov 2026→Q3 2026 earnings showed strong commercial execution for DAYBUE and NUPLAZID, but the ACP-204 Phase 2 trial missed its primary statistical endpoint.
Aug 2026▲The Q2 2026 10-Q disclosed an FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis and detailed advancing competitors in the Rett syndrome market.
Aug 2026▲Q2 2026 earnings showed strong momentum, with DAYBUE sales up 30 percent and NUPLAZID sales up 10 percent year over year. Management raised 2026 DAYBUE guidance following strong STIX adoption.
Jun 2026▲DAYBUE received a positive CHMP recommendation in Europe after an earlier negative review process. This improves the DAYBUE global story, while final European Commission approval remains pending.
May 2026→The Q1 2026 10-Q confirmed product sales already reported by management. NUPLAZID net sales were $166.9 million and DAYBUE net sales were $101.2 million.
May 2026▲Q1 showed strong DAYBUE momentum, with sales up 20 percent year over year and STIX uptake faster than expected. NUPLAZID was softer because of a temporary refill lag that management said had normalized.
Feb 2026▼The 2025 10-K added pressure points around NUPLAZID, including an $11.8 million unfavorable gross-to-net adjustment tied to Medicare rebates and a future Medicare pricing risk.
Feb 2026→Full-year 2025 revenue passed $1 billion and 2026 guidance called for more growth, but DAYBUE's negative CHMP trend vote created a new Europe overhang.
02 Business model

Sales fund the science

ACADIA makes money by selling prescription drugs. NUPLAZID treats hallucinations and delusions linked to Parkinson's disease psychosis. DAYBUE treats Rett syndrome, a rare brain and development disorder.

This model is healthier than many biotech models because the company is commercial stage, cash-flow positive, and has no debt in the internal view. That means its existing products can help pay for research instead of relying only on new stock sales or borrowing.

The weak point is concentration. All product revenue comes from two medicines. If DAYBUE use slows or ACP-204 fails in Phase 3, the long-term growth story gets thinner fast. Competition in the Rett syndrome space is also heating up.

Valuation also matters. The business is better funded than many biotech peers, but Finn valuation scores are modest. Investors are already paying for part of the good commercial news.

03 Product portfolio

What ACADIA sells and studies

Cash cow

NUPLAZID

NUPLAZID is approved in the U.S. for hallucinations and delusions tied to Parkinson's disease psychosis. It is the mature profit engine, with sales reaching $202 million in Q3 2026.

Growth engine

DAYBUE

DAYBUE is the first FDA-approved treatment for Rett syndrome. Q3 2026 net sales were $140 million, as the new STIX powder form continues to help adoption.

Growth engine

DAYBUE in Europe

DAYBUE officially received European Commission approval in Q3 2026. The initial launch phase is starting in Germany.

Option

ACP-204

ACP-204 is a next-generation 5HT2A compound being tested in Alzheimer's disease psychosis. The Phase 2 RADIANT study missed statistical significance on its primary endpoint, but the company is proceeding to Phase 3 with trial modifications.

Option

ACP-211

ACP-211 is a once-a-day oral compound for major depressive disorder. Phase 2 (NORLIGHT) results are expected in the second half of 2027.

Option

ACP-711

ACP-711 is a potential first-in-class GABA-Alpha-3 positive allosteric modulator for essential tremor. A Phase 2 study is delayed slightly to explore higher dosing, expected to begin in 2027.

Option

ACP-271

ACP-271 is a GPR88 agonist progressing through Phase 1 trials.

04 Business segments

Revenue is all product sales

NUPLAZID59%modest
DAYBUE41%growing fast

ACADIA reports as one operating segment, but Q3 2026 product sales were split between NUPLAZID and DAYBUE. The mix below uses Q3 2026 net product sales of $202 million for NUPLAZID and $140 million for DAYBUE.

05 Risk factors

What could break the thesis

ACP-204 Phase 3 trial risk

High impact · High odds

The pipeline is now heavily tied to ACP-204, but the Phase 2 RADIANT study missed its primary statistical goal. The Phase 3 program will rely on trial design optimizations like central raters to achieve a positive outcome.

We watchFDA agreement on statistical modifications for the Phase 3 trial, expected during a Q1 2027 meeting.

Emerging Rett syndrome competitors

High impact · Medium odds

ACADIA currently has a monopoly in Rett syndrome, but new treatments are advancing quickly. UCB, Taysha Gene Therapies, and Neurogene all have pivotal trials underway that could eventually erode DAYBUE market share.

We watchClinical trial readouts from UCB, Taysha, and Neurogene over the next 12 to 24 months.

DAYBUE STIX persistency issues

High impact · Medium odds

Growth is increasingly driven by DAYBUE STIX uptake, bringing back discontinued patients. The key question is whether that demand continues or fades over time.

We watchDAYBUE quarterly net sales, new prescriptions, restarts, and comments on persistency after the STIX launch.

EU commercial execution struggles

Medium impact · Medium odds

With the European Commission approval secured, the focus shifts to commercial launch. Pricing and reimbursement negotiations, starting in Germany, can slow revenue.

We watchCountry-by-country reimbursement updates and German launch metrics in late 2026 and 2027.

NUPLAZID exclusivity and pricing pressure

Medium impact · Medium odds

NUPLAZID could face Medicare price negotiation as early as 2029, and uncertainty remains around a potential six-month pediatric exclusivity extension.

We watchFDA decisions on pediatric exclusivity and any updates on Medicare negotiation timing.
06 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
November 8, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. ACADIA Q3 2026 Earnings Transcript
  2. ACADIA Q2 2026 Form 10-Q
07 Explore the industry

Comparable Biotechnology companies

Companies near ACADIA Pharmaceuticals Inc. in Finn's Biotechnology industry ranking.

Get started with Finn today